1048678-21-2

Basic information

• Product Name: 5-bromo-3-bromomethylpyridine-2-carboxylic acid methyl ester
• Synonyms: 5-bromo-3-bromomethylpyridine-2-carboxylic acid methyl ester
• CAS NO: 1048678-21-2
• Molecular Weight: 308.957
• Mol File: 1048678-21-2.mol

Chemical Properties

• CAS DataBase Reference: 5-bromo-3-bromomethylpyridine-2-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-3-bromomethylpyridine-2-carboxylic acid methyl ester(1048678-21-2)
• EPA Substance Registry System: 5-bromo-3-bromomethylpyridine-2-carboxylic acid methyl ester(1048678-21-2)

Safety Data

• Hazardous Substances Data: 1048678-21-2(Hazardous Substances Data)

Usage

Uses

Methyl 5-Bromo-3-(bromomethyl)picolinate is a useful reactant.

Upstream product

• 156072-86-5 5-bromo-3-methylpyridine-2-carbonitrile 
• 3430-18-0 2,5-dibromo-3-methylpyridine 
• 886365-43-1 5-bromo-3-methylpyridine-2-carboxylic acid 
• 213771-32-5 5-bromo-3-methylpyridine-2-carboxylic acid methyl ester 

Downstream Products

• 1048678-22-3 3-bromo-6-[4-(trifluoromethoxy)benzyl]-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one 
• 1254318-86-9 (S)-4-amino-N-(1-cyano-2-(4-(6-methyl-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)phenyl)ethyl)tetrahydro-2H-pyran-4-carboxamide 
• 1352152-94-3 (S)-tert-butyl 1-(1-amino-3-(4-(6-isopropyl-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)phenyl)-1-oxopropan-2-ylcarbamoyl)cyclohexylcarbamate 
• 1352152-95-4 (S)-tert-butyl 1-(1-cyano-2-(4-(6-isopropyl-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)phenyl)ethylcarbamoyl)cyclohexylcarbamate 
• 1352152-92-1 (S)-1-amino-N-(1-cyano-2-(4-(6-isopropyl-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)phenyl)ethyl)cyclohexanecarboxamide 
• 1352152-15-8 (S)-tert-butyl 1-(1-amino-3-(4-(6-methyl-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)phenyl)-1-oxopropan-2-ylcarbamoyl)cyclohexylcarbamate 
• 1352152-16-9 (S)-tert-butyl 1-(1-cyano-2-(4-(6-methyl-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)phenyl)ethylcarbamoyl)cyclohexylcarbamate 
• 1346809-61-7 3-bromo-5H-pyrrolo[3,4-b]pyridin-7(6H)-one 
• 1352152-27-2 (S)-tert-butyl 1-(1-amino-1-oxo-3-(4-(7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)phenyl)propan-2-ylcarbamoyl)cyclohexylcarbamate 
• 1352152-28-3 (S)-tert-butyl 1-(1-cyano-2-(4-(7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)phenyl)ethylcarbamoyl)cyclohexylcarbamate 
• 1352152-26-1 (S)-1-amino-N-(1-cyano-2-(4-(7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)phenyl)ethyl)cyclohexanecarboxamide 
• 1430058-59-5 2-[(2S)-2-[3-(4-chloro-1-methyl-1H-pyrazol-5-yl)-7-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 
• 1430057-33-2 6-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-3-(4-chloro-1-methyl-1H-pyrazol-5-yl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one 
• 1430058-57-3 2-[(2S)-2-(3-bromo-7-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 

Relevant articles and documents

INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

COMBINATION PRODUCT FOR THE TREATMENT OF CANCEROUS DISEASES

The present invention relates to a product for combination therapies useful for the treatment of cancer diseases. In particular, the invention relates to the combination of an anti-PD-Ll antibody and an MCT4 inhibitor of Formula (I). The therapeutic combination may be utilized for the use in treating a subject having a cancer disease that tests positive for PD-L1 and/or MCT4 expression.

DISUBSTITUTED ALKYNE DERIVATIVES

The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS

The present disclosure provides selective phosphoinositide 3-kinase gamma inhibitors of Formula (I) including (I-a), (I-b), (I-c), and (I-d), or pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of conditions mediated

BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor

INDOLIN-2-ONE DERIVATIVES

The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein the substituents are defined in claim 1. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of s

Fused Pyrazoles as FGFR Inhibitors

The present invention relates to fused pyrazole derivatives, and pharmaceutical compositions including the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS

The present invention provides isoindolinone and pyrrolopyridinone derivatives, as well as their compositions and methods of use, that inhibit the activity of the serine/threonine kinase, Akt, and are useful in the treatment of diseases related to the act

Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease

The present invention relates to a compound having the general formula II, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease

The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.